Lifecore Biomedical (FRA:LDE) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
58 GF Score
Price €4.14
GF Value €4.98
! 3 Warning Signs
View Full Analysis

What is Lifecore Biomedical Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lifecore Biomedical  (FRA:LDE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lifecore Biomedical Cyclically Adjusted PS Ratio Related Terms


Lifecore Biomedical Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Cyclically Adjusted PS Ratio Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.54 0.50 0.39 0.52

Lifecore Biomedical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.58 0.00 0.31 0.45

FRA:LDE vs DERM, ADCT, ANIK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted PS Ratio falls into.


FRA:LDE
58GF Score
Lifecore Biomedical Inc FRA:LDE
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lifecore Biomedical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lifecore Biomedical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.789/333.9520*333.9520
=0.789

Current CPI (Jun. 2026) = 333.9520.

Lifecore Biomedical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 4.291 240.849 5.950
201611 4.560 241.353 6.310
201702 4.633 243.603 6.351
201705 2.116 244.733 2.887
201708 3.520 245.519 4.788
201711 3.743 246.669 5.067
201802 4.204 248.991 5.638
201805 4.261 251.588 5.656
201808 3.853 252.146 5.103
201811 3.948 252.038 5.231
201902 4.701 252.776 6.211
201905 4.673 256.092 6.094
201908 4.280 256.558 5.571
201911 4.426 257.208 5.747
202002 4.808 258.678 6.207
202005 -8.615 256.394 -11.221
202008 3.920 259.918 5.037
202011 3.782 260.229 4.853
202102 1.260 263.014 1.600
202105 -0.723 269.195 -0.897
202108 1.203 273.567 1.469
202111 1.292 277.948 1.552
202202 1.118 283.716 1.316
202205 0.678 292.296 0.775
202208 0.792 296.171 0.893
202211 0.724 297.711 0.812
202302 0.818 300.840 0.908
202305 0.945 304.127 1.038
202308 0.740 307.026 0.805
202311 0.765 307.051 0.832
202402 0.904 310.326 0.973
202405 0.941 314.069 1.001
202408 0.726 314.796 0.770
202411 0.893 315.493 0.945
202502 0.912 319.082 0.955
202505 0.873 321.465 0.907
202509 0.709 324.800 0.729
202512 0.000 324.054 0.000
202603 0.535 330.213 0.541
202606 0.789 333.952 0.789

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €4.14 is trading 16.9% below its estimated GF Value™ of €4.98.

Key valuation signals for FRA:LDE:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €4.98 vs. price of €4.14 (16.9% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
58GF Score

Get the complete analysis for FRA:LDE

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.14
Price
€4.98
GF Value